-+ 0.00%
-+ 0.00%
-+ 0.00%

ZENAS BIOPHARMA ANNOUNCES UPCOMING PRESENTATION OF RESULTS FROM PHASE 3 INDIGO REGISTRATIONAL TRIAL OF OBEXELIMAB IN IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) AT EULAR 2026 CONGRESS

Reuters·05/19/2026 11:05:00

Please log in to view news